Literature DB >> 25168537

The association between socioeconomic status, renal cancer presentation, and survival in the United States: a survival, epidemiology, and end results analysis.

Matthew R Danzig1, Aaron C Weinberg1, Rashed A Ghandour1, Srinath Kotamarti1, James M McKiernan1, Ketan K Badani2.   

Abstract

OBJECTIVE: To determine whether socioeconomic status (SES) predicts the size and local extent of tumors at presentation, and if this association leads to differences in survival.
MATERIALS AND METHODS: The National Cancer Institute's Survival, Epidemiology, and End Results registry was queried for patients diagnosed with renal cancers between 2004 and 2010. Demographic, tumor, survival, and socioeconomic data were obtained. Cancers with T0 classification, nonrenal cell histology, or missing clinical or pathologic data were excluded. An SES measure was created from available metrics. Outcomes analyzed were tumor size, TNM classifications at diagnosis, tumor grade and histology subtype, and survival duration.
RESULTS: A total of 40,212 cases were identified. On regression modeling, lower SES was an independent risk factor for tumor size ≥ 4 cm (P = .003) and for T classification ≥ T2 (P = .040) at presentation, but did not predict histology subtype, positive lymph nodes, or metastasis. Lower SES predicted high-grade disease on univariate analysis (P = .012) but lost significance in the multivariate model. Lower SES was also independently predictive of shortened cancer-specific survival on multivariate analysis after adjusting for available cofactors (lowest vs highest SES quartile; P = .001).
CONCLUSION: This study suggests that low SES is correlated with poorer survival outcomes in renal cancer, and this may be related to a tendency toward larger and more locally advanced tumors at diagnosis. Additional investigation is needed to ascertain whether these effects could be mediated by relatively lower rates of incidental detection via abdominal imaging in disadvantaged populations.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25168537     DOI: 10.1016/j.urology.2014.05.024

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Systemic therapy for metastatic renal cell carcinoma-is timing everything?

Authors:  Ritesh R Kotecha; Martin H Voss
Journal:  Ann Transl Med       Date:  2019-09

2.  Race and sex disparities in long-term survival of oral and oropharyngeal cancer in the United States.

Authors:  Nosayaba Osazuwa-Peters; Sean T Massa; Kara M Christopher; Ronald J Walker; Mark A Varvares
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-28       Impact factor: 4.553

3.  Factors Explaining Socio-Economic Inequalities in Cancer Survival: A Systematic Review.

Authors:  Nina Afshar; Dallas R English; Roger L Milne
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

4.  The effects of clinical and sociodemographic factors on survival, resource use and lead times in patients with high-grade gliomas: a population-based register study.

Authors:  Jenny Bergqvist; Hanna Iderberg; Johan Mesterton; Roger Henriksson
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

5.  Pediatric genitourinary tumors: Distribution, demographics, and outcomes.

Authors:  Azadeh Nazemi; Siamak Daneshmand; Andy Chang
Journal:  Pediatr Investig       Date:  2022-03-31

6.  Analysis and Prediction of the Survival Trends of Patients with Clear-Cell Renal Cell Carcinoma: A Model-Based Period Analysis, 2001-2015.

Authors:  Sicong Du; Yu Zhong; Shuai Zheng; Jun Lyu
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.